Drug Profile


Alternative Names: ACR-16; ASP-2314; FR-310826; Huntexil; TV-7820

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroSearch Sweden AB
  • Developer NeuroSearch Sweden AB; Teva Pharmaceutical Industries
  • Class Antiparkinsonians; Antipsychotics; Neuropsychotherapeutics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Glutamate modulators; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Huntington's disease
  • Discontinued Parkinson's disease; Schizophrenia

Most Recent Events

  • 22 Apr 2017 Interim efficacy data from the phase II Open-HART trial in Huntington's disease presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 22 Apr 2017 Efficacy data from the phase II Pride-HD in Huntington's disease presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 17 Mar 2017 Teva Branded Pharmaceutical Products, R&D initiates a phase I trial for Huntington’s disease in Germany (PO, Capsule) (NCT03019289)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top